Gelesis Holdings, Inc. · OTC:GLSHQ
Gelesis — Investor Presentation (September 2023)
24 slides from Gelesis's investor presentation, Sep 6, 2023
Slide 1: Gelesis, Makers of Plenity
GELESIS Makers of Plenity: GELESIS
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements, estimates, targets and projections in this presentation may constitute “forward-looking statements” within the meaning of the federal securities laws. The words “anticipate,” “believe,” continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,”
Slide 3: The Gelesis Opportunity
The Gelesis Opportunity Proven commercialized and promotionally responsive brand Potential near-term catalysts: Transition to OTC with improved customer acquisition efficiency and 2-3X larger target market Geographic partnership potential (already approved in EU as OTC) Food products & nutritional s
Slide 4: Changing the Lives of Millions of People Struggling with Excess Weight
Changing the Lives of Millions of People Struggling with Excess Weight Plenity is our FDA-cleared weight management product Since we launched Plenity Rx, we have helped over 200,000 people and generated $42M of revenue* We now plan to multiply our impact with a potential OTC / non-Rx launch * Cumula
Slide 5: Majority of Americans Want to Lose <40 Pounds
Majority of Americans Want to Lose <40 Pounds1 Most of Them Don’t Want / Qualify for & Can’t Afford Rx Drugs US Population2 50M 47M 33M 23M 19M BMI 25-27 BMI 27-30 BMI 30-35 BMI 35-40 BMI >40 Diet & exercise Hope to lose 10-40 pounds don’t work Label Covers >150M Americans of which 61million interes
Slide 6: New Therapies Have Ignited the Category, but They Have Limitations
New Therapies Have Ignited the Category, but They Have Limitations GLP-1 Limitations • Affordable & easily accessible as OTC Access & "can cost $1,400 a month..." • Could eventually be a step through Affordability: "we'd bankrupt the health system." therapy for GLP1s • Widest label of any Rx therapy
Slide 7: To Impact Millions Who are Waiting, the Ideal Weight Loss Product Should Be
To Impact Millions Who are Waiting, the Ideal Weight Loss Product Should Be 1. Safe 2. Effective 3. Affordable & Easy & Proven & Accessible To date, other weight loss products or services have fallen short 7
Slide 8: Meet Plenity: FDA Cleared, Clinically Proven & Well Tolerated
Meet Plenity: FDA Cleared, Clinically Proven & Well Tolerated Designed to make you Feel Fuller, Eat Less, and Lose Weight 1. Safety 2. Effective 3. Affordable & Ease & Proven & Accessible Safety: Effectiveness: 6 out Affordable: Costs Unprecedented of 10 people in our $1.75 per dose and safety profi
Slide 9: Safety & Ease
Safety & Ease Plenity Breakthrough Technology is the Only Superabsorbent Hydrogel Made Entirely from Naturally Derived Building Blocks Within minutes, the capsules dissolve and form a large volume of small non-aggregating gel pieces, with Cucumber composition & firmness similar to ingested raw veget
Slide 10: Gelesis Patents
Gelesis Patents Plenity protection through 2028-2035 with issued and pending patents (in US and ex-US) broadly covering 9 compositions of matter, methods of use and methods of production, with potential for extensions Patent Families Composition Patents covering Plenity (GS100) and GS200 composition
Slide 11: Safety & Ease: Feel Fuller Throughout the Day with Less Food
Safety & Ease: Feel Fuller Throughout the Day with Less Food Not Absorbed, Not Habit Forming, Induces Satiety and Weight Loss by Increasing the Volume and Firmness of the Ingested Meals without any Additional Calories Capsules taken Create small Gel pieces Increasing the Not absorbed & with water ge
Slide 12: Effective & Proven
Effective & Proven Robust Efficacy and Safety in Clinical Trials and the Real World Responders Super Responders Adults achieving 5% or greater weight loss Adults achieving 10% or greater weight loss in only 24 weeks in only 24 weeks 6 out of 26% were “super-responders” to Plenity, losing on average
Slide 13: Effective & Proven: Strong Sales Growth from Consumer Awareness Marketing
Effective & Proven Strong Sales Growth from Consumer Awareness Marketing What We Have Proven Cumulative Members Media Ability to obtain customers Campaign1 Over 200k new customers since launch Product message resonates in market Over 200% revenue growth in 1H-22 vs. 1H-21 shows immediate and robust
Slide 14: Effective & Proven, with High Consumer Satisfaction
Effective & Proven, with High Consumer Satisfaction 14
Slide 15: Affordable & Accessible
Affordable & Accessible Plenity OTC Advantages over Rx 2X Larger Addressable Market 26M targeted population for Rx vs. 61M for OTC1 Anticipated Significant Reduction in Single digit purchase rate2 as Rx vs 30% for e- CAC commerce benchmark (anticipated)3 Limited to only Rx channels vs. multiple as O
Slide 16: Plenity OTC: Why Now?
Plenity OTC: Why Now? Accumulated safety record with over 200,000 people. Unprecedented real-world safety and tolerability consistent with the clinical studies Customers want easy access: ~98% drop off from Rx website1. Many also prefer the privacy and control of their weight loss journey Growing in
Slide 17: OTC Makes the Purchase Process Simpler and Easier
OTC Makes the Purchase Process Simpler and Easier Only 3 Steps Without Need for Medical Data or Photos... Rx steps required by consumer: OTC steps required by consumer: 20+ min process ~1 min process 1 Starts online visit 5 Provides credit card info 1 Clicks “buy Plenity” 2 Begins questionnaire 6 Dr
Slide 18: New Distribution Opportunities as OTC Drive Broader Access
New Distribution Opportunities as OTC Drive Broader Access Current Distribution Limited to Telehealth & Traditional Prescribing E-commerce Partnerships / Non-traditional Brick & Mortar • Myplenity.com • Health and Wellness Outlets: e.g. • Retail pharmacies • Telehealth (non-Rx) Equinox, Lifetime, •
Slide 19: Strategic Focus Over Next 12 Months
Strategic Focus Over Next 12 Months By Switching to OTC, Gelesis Aims to Make Plenity a Blockbuster Over Time Access: Transformational Profitability: Improve margins while Reach: Continue to change in go-to-market strategy driving towards profitability within 2 expand global footprint driving effici
Slide 20: Plenity Regulatory Approvals
Plenity Regulatory Approvals Commercial-Stage Status Across the Globe United States European Union China FDA-Cleared Rx CE Mark for In process of product, with OTC/non-Rx product obtaining Chinese submission already in the European regulatory approval underway to Economic Area with commercial transi
Slide 21: Future Dosage Forms Could be Administered in Multiple Forms
Future Dosage Forms Could be Administered in Multiple Forms: In capsules (gelatin or vegetarian) or sachets As a single ingredient or in combination with other supplements In dry foods such as food bars Coating the GS200 particles with a moisture barrier prevents hydration in the mouth and delays th
Slide 22: Future Dosage Forms: Food Bar Prototype
Future Dosage Forms: Food Bar Prototype Food bars enhanced by GS200 have the same taste and texture, yet will create up to 5X more volume in the stomach without adding any calories The 40g bar prototype in the photos has 2g of GS200. In the stomach it will create similar volume, firmness and composi
Slide 23: Why Invest in Gelesis Now?
Why Invest in Gelesis Now? Proven commercialized asset with $42M of revenue since launch, >200k customers & 4-star reviews, 6 out of 10 have average weight loss of 10% body weight in just 6 months, strong patent portfolio, manufacturing & scale-up complete Potential catalysts include: -Transition to
Slide 24: Broad Network of Top Clinical Advisors
Broad Network of Top Clinical Advisors Past & Present Collaborators Louis J. Aronne, Lee M. Kaplan, Arne Astrup, M.D. Caroline Apovian, M.D. James Hill, Ph.D. M.D., FACP M.D., Ph.D. • Professor of Medicine & • Sanford I. Weill • Director of the Obesity, • Professor of Medicine and Pediatrics, Univer
Gelesis Holdings — Investor Presentation (September 2023) on 6ix